Despite megamerger deal speculation, Novartis has been pledging bolt-on deals, and the latest buzz says it has a $2.6 billion target in its sights.
Amid a wave of pricing pressure and consolidation in the generics industry, another sale is brewing.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
Impax Labs CEO Paul Bisaro, who has extensive experience building companies through M&A, is reportedly in talks with competitor Amneal.
Catalent has agreed to pay $950 million to buy Cook Pharmica and its extensive biologics manufacturing operation in Bloomington, Indiana.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
Fosun Pharma has cut back its offer for Gland Pharma just enough to circumvent the Indian government’s scrutiny.
Teva unveiled terms to sell its remaining women's health products, gaining $1.38 billion that'll go toward paying down debt.
Teva earlier this week inked a pact to sell off a women’s health product—and now it’s closing in on a deal to divest that business’s ex-U.S. assets.
Monday was quite the day for Teva. In addition to naming a new CEO, the company unveiled the first of the asset sales it’s promised to pay down debt.
Kite Pharma CEO Arie Belldegrun turned a single buyout bid into a $12 billion deal by capitalizing on suitor Gilead’s need to make a game-changing deal.
A new report highlights some positive news from a pharma employment point of view.